Lenalidomide vs. Placebo for Multiple Myeloma Patients Following a Single ASCT
Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).
In the updated analysis, the current median follow up for overall survival (OS) was 65 months. When it was previously published, the OS was 34 months. The longer follow up has shown a significant improvement in time to progression for lenalidomide vs placebo.
The patients on the lenalidomide arm have not yet reached a median OS; these patients continue to do very well.
Sarah Holstein, MD, PhD, assistant professor of oncology, Roswell Park Cancer Institute, discusses a randomized study that compared lenalidomide with placebo for patients with multiple myeloma, following a single autologous stem cell transplant (ASCT).
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
